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ABSTRACT 23 
Introduction: Skeletal muscle carnosine content can be increased through β-alanine 24 
supplementation, but the maximum increase achievable with supplementation is unknown. No 25 
study has investigated the effects of prolonged supplementation on carnosine-related genes or 26 
exercise capacity. Purpose: To investigate the effects of 24-weeks of β-alanine supplementation 27 
on muscle carnosine content, gene expression and high-intensity cycling capacity (CCT110%). 28 
Methods: Twenty-five active males were supplemented with 6.4 g·day
-1
 of sustained release β-29 
alanine (BA) or placebo (PL) over a 24-week period. Every 4 weeks participants provided a 30 
muscle biopsy and performed the CCT110%. Biopsies were analysed for muscle carnosine content 31 
and gene expression (CARNS, TauT, ABAT, CNDP2, PHT1, PEPT2 and PAT1). Results: 32 
Carnosine content was increased from baseline at every time point in BA (all P<0.0001; Week 4: 33 
+11.37±7.03 mmol·kg
-1
dm, Week 8: +13.88±7.84 mmol·kg
-1
dm, Week 12: +16.95±8.54 34 
mmol·kg
-1
dm, Week 16: +17.63±8.42 mmol·kg
-1
dm, Week 20: +21.20±7.86 mmol·kg
-1
dm, 35 
Week 24: +20.15±7.63 mmol·kg
-1
dm), but not PL (all P=1.00). Maximal changes were 36 
+25.66±7.63 mmol·kg
-1
dm (range: +17.13 to +41.32 mmol·kg
-1
dm), and absolute maximal 37 
content was 48.03±8.97 mmol·kg
-1
dm (range: 31.79 to 63.92 mmol·kg
-1
dm). There was an effect 38 
of supplement (P=0.002) on TauT; no further differences in gene expression were shown. 39 
Exercise capacity was improved in BA (P=0.05) with possible to almost certain improvements 40 
across all weeks. Conclusions: Twenty-four weeks of β-alanine supplementation increased 41 
muscle carnosine content and improved high-intensity cycling capacity. Downregulation of TauT 42 
suggests it plays an important role in muscle carnosine accumulation with β-alanine 43 
supplementation, while the variability in changes in muscle carnosine content between 44 
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individuals suggests that other determinants other than the availability of β-alanine may also bear 45 
a major influence on muscle carnosine content. 46 
 47 
Keywords: Skeletal muscle carnosine, chronic β-alanine supplementation, carnosine-related 48 
genes, high-intensity cycling capacity, muscle biopsy  49 
50 
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INTRODUCTION 51 
The physiological roles of carnosine (β-alanyl-L-histidine) are pleiotropic and have been 52 
associated with effects on muscle buffering capacity, metal-ion chelation and antioxidant 53 
scavenging (9). Dietary supply of histidine-containing dipeptides is a major determinant of 54 
skeletal muscle carnosine content (18) and increases with β-alanine supplementation have been 55 
shown using chromatographic (i.e., HPLC) quantification of muscle biopsy samples (15, 17, 19) 56 
and magnetic resonance spectroscopy (3, 12, 13).  57 
 58 
Stellingwerff et al. (33) demonstrated that the rate of increase in muscle carnosine over 4 weeks 59 
was linearly related to the β-alanine dose given (1.6 and 3.2 g∙day-1), while the absolute change 60 
was dependent on the total amount ingested. An average dose of 5.2 g∙day-1 for 4 weeks 61 
increased carnosine content in the m. vastus lateralis from 19.9±1.9 to 30.1±2.3 mmol∙kg-1dm; a 62 
further 6 weeks of supplementation at 6.4 g∙day-1 increased carnosine content to 34.7±3.7 63 
mmol∙kg-1dm (19). These data demonstrate that maximum accumulation of carnosine takes more 64 
than 4 weeks of β-alanine supplementation at a mean dose of 5.2 g∙day-1. It is unknown if there is 65 
an upper limit to muscle carnosine content and whether this differs between individuals. It is 66 
possible that the ergogenic and therapeutic benefits of an increase in muscle carnosine may be 67 
maximised when this reaches its peak content. It would be of interest to determine the kinetics of 68 
carnosine accumulation in muscle with prolonged β-alanine supplementation. 69 
 70 
A number of genes and their resulting proteins regulate the processes affecting muscle carnosine 71 
content; the uptake of β-alanine and carnosine into skeletal muscle, the local synthesis of 72 
carnosine, the hydrolysis of carnosine, and the transamination of β-alanine. The genes 73 
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controlling these processes are: CARNS (carnosine synthesis), TauT, PAT1, ATB
0,+
 (β-alanine 74 
transport), CNDP1, CNDP2 (carnosine hydrolysis), ABAT (β-alanine transaminase), and PEPT1, 75 
PEPT2, PHT1, PHT2 (carnosine/histidine transport). The expression of some of these genes 76 
have been examined (14), but the influence of β-alanine supplementation on their expression 77 
remains unknown in humans. In particular, transport of β-alanine into muscle (via TauT), 78 
synthesis of muscle carnosine (via CARNS) and deamination of β-alanine (via ABAT) have been 79 
suggested to play important roles in the regulation of carnosine synthesis (14). The examination 80 
of the changes in expression of carnosine-related genes following prolonged β-alanine 81 
supplementation could provide important information as to the mechanisms by which increased 82 
β-alanine availability increases muscle carnosine content.  83 
 84 
The efficacy of β-alanine supplementation to improve exercise capacity and performance has 85 
been demonstrated (20, 31). Improvements during a high-intensity cycling capacity test at 110% 86 
of maximum power output (CCT110%) have been verified independently, showing that time to 87 
exhaustion (TTE) was improved by 11.9% (19), 12.1% (30) and 14.0% (11). The improved 88 
exercise capacity shown by Hill et al. (19) was linear to changes in muscle carnosine, although 89 
no studies have examined the association between muscle carnosine and exercise changes over a 90 
longer time period with multiple data points.  91 
 92 
We aimed to determine whether: a) a ceiling for carnosine accumulation in skeletal muscle exists 93 
following twenty-four weeks of β-alanine supplementation, b) carnosine content influences the 94 
expression of genes responsible for regulating carnosine in muscle, and c) the changes in muscle 95 
carnosine are related to changes in high-intensity exercise capacity. We hypothesised that: a) 96 
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long-term β-alanine supplementation would lead to saturation of the muscle carnosine content, b) 97 
prolonged supplementation would downregulate genes involved in the control of the carnosine 98 
content in muscle, and c) that the increases in muscle carnosine would be paralleled by 99 
improvements in exercise capacity.  100 
101 
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METHODS 102 
Participants 103 
Twenty-five physically active healthy males (age 27 ± 4 y, height 1.75 ± 0.09 m, body mass 78.9 104 
± 11.7 kg), who participated in exercise (e.g., running, cycling, team sports) 1-3 times per week, 105 
volunteered. Participants were requested to maintain similar levels of physical activity and 106 
dietary intake for the duration of the study and compliance with this request was verbally 107 
confirmed with individuals throughout. Individuals completed a food intake diary during weeks 108 
4-8 and 16-20 on two non-consecutive weekdays and one weekend day. Energy and 109 
macronutrient intake was analysed by a nutritionist using specific software (Avanutri, Rio de 110 
Janeiro, Brazil). Habitual consumption of β-alanine was calculated based upon specific tables 111 
taken from the literature (1, 24). Exclusion criteria included, i) supplementation of creatine or β-112 
alanine in the 6 months prior to the study, ii) ongoing supplementation of any dietary supplement 113 
except carbohydrate and whey protein, and iii) vegetarian diet. The study was first approved by 114 
the institution’s Ethical Advisory Committee. Participants provided written informed consent 115 
after completing a health screen. 116 
 117 
Experimental Design 118 
Participants attended the laboratory on nine occasions. The first two visits were for the 119 
determination of maximal cycling power output and a familiarisation with the exercise protocol. 120 
The remaining seven visits were for the completion of the main trials, each separated by 4 121 
weeks; one main trial was completed before supplementation (Week 0) followed by one main 122 
trial every 4 weeks for 24 weeks (Weeks 4–24) during double-blinded supplementation with β-123 
alanine or placebo (Panel A, Figure 1).  124 
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 125 
Participants were randomly allocated to receive either β-alanine (BA) or placebo (PL) in a 2:1 126 
ratio (i.e., two participants were allocated in BA for each participant in PL); individuals were 127 
matched for maximum cycling power output (Wmax; BA = 283 ± 42 W, PL = 286 ± 52 W) using 128 
a block randomisation method.(2) An unbalanced design was adopted a priori in order to 129 
minimise the number of individuals being biopsied (12). Individuals were supplemented for 24 130 
weeks with either 6.4 g·d
-1
 β-alanine (CarnoSyn®, NAI, USA) or an equivalent amount of 131 
placebo (maltodextrin; NAI, USA); two 800 mg tablets taken four times per day at 3–4 hour 132 
intervals. Participants completed a log to verify compliance (BA: 95 ± 6%; PL: 93 ± 6%); one 133 
individual, who was in BA, did not adhere to the supplementation protocol and was thus 134 
removed from any analyses. Blinding occurred via an outside researcher not involved in direct 135 
data collection who provided the researchers with identical white pots containing only participant 136 
names.  137 
 138 
Experimental Procedures 139 
Preliminary Testing 140 
Height and body mass (BM) were recorded upon arrival at the first laboratory session, and BM 141 
was further recorded at Weeks 12 and 24. Wmax was determined by completing a graded cycling 142 
exercise test to exhaustion (Lode Excalibur, Germany). The participants’ second visit to the 143 
laboratory comprised a familiarisation session of the main exercise protocol (described below).  144 
 145 
Main Trials 146 
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Participants abstained from alcohol, caffeine and strenuous exercise and completed a food record 147 
for the 24 h period prior to the initial trial. They adopted the same dietary intake prior to each 148 
trial. Participants arrived at the laboratory at the same time of day a minimum of 2 h following 149 
their last consumption of food and 4 h since their last supplement ingestion. A cannula was 150 
inserted into the antecubital vein for venous blood collection. The participants then underwent a 151 
muscle biopsy of the m. vastus lateralis before performing the CCT110% (Panel B, Figure 1). 152 
 153 
Muscle biopsies 154 
Muscle biopsies were taken at rest using a 5 mm biopsy Allandale needle (Northern Hospital 155 
Supplies, Edinburgh, UK) by a method adapted from Bergstrom (6), described in detail 156 
elsewhere (27). The dominant leg was prepared through an incision along the m. vastus lateralis 157 
muscle under local anaesthesia (lidocaine 1%, Linisol) of the skin. Two muscle samples (~50 mg 158 
for HPLC analysis and ~50 mg for polymerase chain reaction [PCR] analysis) were taken and 159 
immediately frozen in liquid nitrogen and stored at -80 ºC. All biopsies followed the same 160 
standardised pattern across individuals. The location of each initial biopsy was at a point 25 cm 161 
proximal from the tuberositas tibiae and 5 cm lateral from the midline of the femoral course. A 162 
second incision was performed adjacent (~1 cm) to the first. Thereafter, the incisions performed 163 
in the weeks following were made superior to the previous ones, resulting in three pairs of 164 
parallel incisions and one single incision at the most superior point.   165 
 166 
Chromatographic determination of carnosine 167 
Total muscle carnosine content was determined by HPLC (Hitachi, Hitachi Ltd., Tokyo, Japan), 168 
as per Mora et al. (26). All chromatography was carried out at room temperature. Samples were 169 
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analysed in duplicate and injected via an auto sampler using a cut injection method with a total 170 
aspirated volume of 70 µL; 30 µL was discarded, 10 µL injected for analysis and the remaining 171 
30 µL also discarded. Prior to all injections, samples were visually inspected for air bubbles, any 172 
of which were subsequently removed manually by the experimenter. Standard curves for 173 
carnosine were performed prior to each analysis session using concentrations of 0.1, 0.5, 1, 2.5, 174 
and 5 mM, showing excellent linearity (R
2
=0.996±0.005).  175 
 176 
The column used for chromatographic separation was an Atlantis HILIC silica column (4.6×150 177 
mm, 3 μm; (Waters, Massachusetts, USA) attached to an Atlantis Silica column guard (4.6×20 178 
mm, 3 μm). The method used two mobile phases: Mobile phase A: 0.65 mM ammonium acetate, 179 
in water/acetonitrile (25:75) (v/v). Mobile phase B: 4.55 mM ammonium acetate, in 180 
water/acetonitrile (70:30). The pH of both solutions was adjusted to 5.5 using hydrochloric acid 181 
and thereafter filtered under vacuum through a 0.2 μm filter membrane. 182 
  183 
The separation condition comprised of a linear gradient from 0 to 100% of solvent B in 13 min at 184 
a flow rate of 1.4 mL∙min-1. Separation was monitored using an ultraviolet detector at a 185 
wavelength of 214 nm. The column was equilibrated for 5 min under the initial conditions before 186 
each injection. Quantification was performed using peak areas, which were calculated by 187 
computer software coupled to the chromatographer and individually inspected for error and 188 
consistency by a researcher. Peak area for the standard curve was plotted and a regression 189 
equation obtained, from which interpolations were used to calculate the content. Limits of 190 
detection for the current method were 0.5125 mmol·kg
-1
dm and the inter-assay coefficient of 191 
variation (CV) of carnosine measurement of the same freeze-dried muscle extracted separately 192 
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on nine occasions was 0.9±1.2%. The intra-assay CV of carnosine between duplicate injections 193 
of all analyses (N=175) was 4.0±4.5%. To determine the reliability of the extraction method, 194 
several samples (N=11) were reanalysed following a new extraction phase, showing a variation 195 
of 2.5±2.1% from initial content. 196 
 197 
Real-time PCR  198 
Real time PCR was used to determine the expression of selected genes related to carnosine 199 
metabolism; CARNS, TauT, ABAT, CNDP1, CNDP2, PAT1, ATB
0,+
, PEPT1, PEPT2, PHT1 and 200 
PHT2. The reference gene used was EEF1A1. Primer synthesis was outsourced (IDT, Iowa, 201 
USA) and primer sets are shown in Supplemental Digital Content 1 (Table, Supplemental Digital 202 
Content 1, Forward and reverse primer sets). Standardisation of primers revealed good 203 
expression at forward and reverse concentrations of 100 mM for PHT1, 200 mM for TauT, 300 204 
mM for CNDP2, PEPT2 and PAT1, and 400 mM for CARNS and ABAT. There was poor or no 205 
expression of CNDP1, PepT2, ATB
0,+ 
or PHT2 using concentrations between 100 and 400 mM; 206 
therefore, expression of these genes was not performed.  207 
 208 
Freeze-dried muscle was homogenized and total RNA isolated using Trizol reagent (Invitrogen, 209 
Carlsbad, California). Nucleic acid concentration (DNA and RNA) was determined by 210 
measuring the optical density at 260 nm with a micro spectrophotometer (NanoDrop ND2000, 211 
Thermo Scientific). RNA purity was determined by calculating the absorbance ratio at 260 nm 212 
and 280 nm, and RNA integrity checked on a 1% agarose gel stained with ethidium bromide. A 213 
10 μL volume containing a total of 1 μg of RNA completed with ultrapure water was added to 10 214 
μL of a specific cDNA reverse transcription kit solution (2X RT, Applied Biosystems, Thermo 215 
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Fisher Scientific, Waltham, USA). The reverse transcription reaction was performed at 25
o
C for 216 
10 min, followed by 37
o
C for 120 min and 5 min at 85
oC according to the manufacturers’ 217 
instructions.  218 
 219 
Real-time PCR for each gene was performed in duplicate with a 2 μL reaction volume of 5–20 220 
ng cDNA, 11 μL SYBR Green Master Mix (Applied Biosystems, California, USA), 100–400 221 
mM of each primer and completed with water to make 22 μL. Gene expression analyses were 222 
carried out using the following cycle parameters: “hold” at 95oC for 20 s; 40 “cycles” of 95oC for 223 
3 s, and 60
o
C for 30 s; “melt” consisting of a gradual ramp from 65 to 95oC at an increase of 224 
1
o
C·s
-1
. The fluorescence intensity was quantified and amplification plots analysed by a 225 
sequence detector system (Rotor Gene-Q, Qiagen, Hilden, Germany). The intra-assay CV for the 226 
comparative cycle threshold (Ct) between the duplicate injections was between 4.5 and 7.5% for 227 
all genes measured. Results were obtained using the comparative Ct method. Delta-Ct (DCt) 228 
values were calculated in every sample for each gene of interest as follows: Ct(gene of interest) – 229 
Ct(reference gene). Relative changes in the expression level of the genes (DDCt) were calculated 230 
by subtraction of the DCt at baseline (Week 0) from the corresponding DCt at the time points of 231 
interest (Weeks 4 – 24). Finally, relative quantification (fold change) was calculated using the 2-232 
DDCt
 equation (34).  233 
 234 
Exercise protocols 235 
Wmax and CCT110% 236 
Each individual performed a Wmax test with results subsequently used to perform the CCT110% in 237 
all subsequent sessions, as described by Saunders et al. (32). Time-to-exhaustion (TTE, s) was 238 
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recorded as the outcome measures for all tests. The CCT110% has been shown to be a reliable test 239 
with a CV of 4.4% for TTE following a solitary familiarisation session (32). The CV between the 240 
familiarisation and baseline time trials in the current study was 4.9 ± 3.4 for TTE; this value 241 
(4.9%) was used to determine improvements above the variation of the test. 242 
 243 
Blood collection and analyses 244 
Finger-prick blood samples were taken pre-, immediately post- and 5-min post-exercise and 245 
analysed for lactate concentration (Accutrend Lactate, Roche Diagnostics, Switzerland). Venous 246 
blood samples were taken at identical times from the antecubital vein using heparin-coated 247 
syringes and analysed for blood pH, bicarbonate and base excess (Rapid Point 350, Siemens, 248 
Germany). The pre-, immediately post- and 5-min post-exercise intra-assay CVs for pH, 249 
bicarbonate and base excess ranged from 0.07±0.03% to 2.77±2.2%. Samples were taken with 250 
the individuals in a supine position except immediately post-exercise, which was taken in a 251 
seated upright position while the participant remained on the cycle ergometer.  252 
 253 
Statistical Analyses 254 
Data were analysed using the SAS statistical package (SAS 9.2, SAS Institute Inc., USA), and 255 
are presented as mean±1SD unless stated. Muscle carnosine, gene expression and exercise data 256 
were analysed using mixed model analysis with individuals assumed as a random factor and 257 
supplementation (2 levels; BA and PL) and week (7 levels; Week 0-24) assumed as fixed factors. 258 
Tukey post-hoc tests were performed whenever a significant F-value was obtained and the 259 
significance level was set at P≤0.05 and a tendency towards an effect was set at P<0.1. 260 
Magnitude based inferences (MBIs; (5, 21)) were used to determine the practical significance of 261 
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β-alanine on CCT110%; the smallest worthwhile improvement in TTE was 3.56 s (32). The means 262 
and SDs for BA and PL were used to calculate effect sizes for muscle carnosine and TTE (22). 263 
Blood data were analysed using a mixed model with individuals assumed as a random factor and 264 
supplementation (2 levels; BA and PL), week (7 levels; Weeks 0 to Week 24) and time (3 levels; 265 
Pre-exercise, Post-exercise, 5-min Post-exercise) assumed as fixed factors. Body mass was 266 
analysed using a mixed model with individuals assumed as a random factor and supplementation 267 
(2 levels; BA and PL) and week (3 levels; Week 0; Week 12; Week 24) assumed as fixed factors. 268 
Food intake was analysed using a mixed model with individuals assumed as a random factor and 269 
supplementation (2 levels; BA and PL) and week (2 levels; Weeks 4-8 and Weeks 16-20) 270 
assumed as fixed factors. Pearson’s correlations were performed to determine any associations 271 
between initial muscle carnosine content and absolute changes over time. 272 
273 
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RESULTS 274 
Muscle carnosine 275 
There were no significant differences in pre-supplementation (Week 0) carnosine content 276 
between BA (22.37±4.46 mmol·kg
-1
dm) and PL (23.18±5.89 mmol·kg
-1
dm; P=1.00). There was 277 
a main effect of supplementation (P<0.0001) and week (P<0.0001), and a supplementation × 278 
week interaction (P<0.0001). Carnosine content increased from Week 0 at every time point in 279 
BA (all P<0.0001; Week 4: +11.37±7.03 mmol·kg
-1
dm, Week 8: +13.88±7.84 mmol·kg
-1
dm, 280 
Week 12: +16.95±8.54 mmol·kg
-1
dm, Week 16: +17.63±8.42 mmol·kg
-1
dm, Week 20: 281 
+21.20±7.86 mmol·kg
-1
dm, Week 24: +20.15±7.63 mmol·kg
-1
dm) with no changes across time 282 
in PL (all P=1.00; Figure 2). Effect sizes from Week 0 were all huge in BA (Week 4: 1.96; 283 
Week 8: 1.93; Week 12: 2.24; Week 16: 2.25; Week 20: 2.86; Week 24: 2.81) and ranged from 284 
negligible to medium effects in PL (0.06 to -0.48).  285 
 286 
Baseline content (Week 0) ranged from 11.67 to 28.97 mmol·kg
-1
dm in BA, and 15.14 to 34.89 287 
mmol·kg
-1
dm in PL. All individuals increased muscle carnosine content above baseline levels. 288 
The absolute maximal changes in muscle carnosine was +25.66±7.63 mmol·kg
-1
dm, ranging 289 
from +17.13 to +41.32 mmol·kg
-1
dm. The absolute maximal content was 48.03±8.97 mmol·kg
-
290 
1
dm, ranging from +31.79 to +63.92 mmol·kg
-1
dm (Table 1). The time-to maximal content was 291 
17±7 weeks and ranged from 4 to 24 weeks; one individual showed maximal carnosine content 292 
at Week 4, four at Week 12, one at Week 16, four at Week 20 and five at Week 24. Initial 293 
muscle carnosine content (Week 0) was significantly correlated to the absolute carnosine content 294 
at Weeks 8 (r=0.52, P=0.05), 16 (r=0.58, P=0.03) and 20 (r=0.57, P=0.03), but not weeks 4 295 
(r=0.29, P=0.29), 12 (r=0.48, P=0.07) or 24 (r=0.37, P=0.18). There was a significant 296 
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correlation between muscle carnosine content at Week 0 and the absolute maximal content with 297 
BA (r=0.53, P=0.04). There were no significant correlations between initial muscle carnosine 298 
content and the delta change in carnosine at any week (all P>0.05) or the delta maximal change 299 
(r=0.04, P=0.90) 300 
 301 
Gene expression 302 
There was no effect of supplement, week or any interaction effects for CARNS, ABAT, CNDP2, 303 
PAT1, PEPT2 or PHT1 (all P>0.05). There was a significant effect of supplement (P=0.002) for 304 
TauT, with lower values over time in BA (-36.4%, -39.4%, -27.3%, -56.8%, -46.3% and -35.0% 305 
at Weeks 4, 8, 12, 16, 20 and 24; Figure 3), although no effect of week (P=0.31) or an 306 
interaction (P=0.59) was shown. There were no significant correlations between muscle 307 
carnosine content and any gene at Week 0 (all P>0.05).  308 
 309 
CCT110% 310 
Exercise capacity was not significantly different between BA and PL at Week 0 (P=1.00, Figure 311 
2). There was a main-effect of supplement (P=0.05), and an interaction effect (supplement × 312 
week, P=0.05), although post-hoc analyses only revealed Week 20 to be significantly different 313 
from Week 0 (P=0.02, Figure 2). TTE was improved from Week 0 in BA at all time points but 314 
not in PL (Table 2). MBIs showed possible to almost certain improvements across all weeks in 315 
BA compared to Week 0; similarly, ES were greater in BA vs. PL at all time points (Table 2).  316 
 317 
Four individuals in BA improved above the variation of the test (>4.9%) at every time point.A 318 
further two individuals improved exercise capacity in all but one week with BA. Six individuals 319 
 17 
in BA had an improved exercise capacity at between 2 and 4 time points during supplementation 320 
and the remaining three showed no improvements at any time point. The week of 321 
supplementation corresponding to each individual’s best performance was variable, with two 322 
individuals showing best performance times following four weeks of supplementation, and two 323 
following eight weeks. One individual’s best performance was following twelve weeks, three 324 
following sixteen weeks, four after twenty weeks and three at the final time point. No individual 325 
showed maximal exercise improvements at their individual maximal muscle carnosine content. 326 
Muscle carnosine content was significantly correlated to TTE in BA (r=0.82, r
2
=0.68, P=0.02), 327 
but not PL (r=0.32, r
2
=0.10, P=0.49; Supplemental Digital Content 2, Muscle carnosine content 328 
and time-to-exhaustion in BA). Absolute changes in muscle carnosine and TTE were 329 
significantly correlated (r=0.804, r
2
=0.65, P=0.05; Supplemental Digital Content 2, absolute 330 
changes in muscle carnosine content and time-to-exhaustion in BA) for BA. No significant 331 
correlation between change in muscle carnosine and exercise capacity were shown in PL (all 332 
P>0.05).  333 
 334 
There was no effect of supplement or week on any blood variable (all P>0.05) although there 335 
was a significant effect of time on all blood measures (all P<0.001); blood lactate was increased 336 
and pH, bicarbonate and base excess were decreased following exercise compared to pre-337 
exercise (Table, Supplemental Digital Content 3, Blood pH, bicarbonate, base excess and 338 
lactate). There were no interactions shown for blood lactate, pH, bicarbonate and base excess (all 339 
P>0.05).  340 
 341 
Dietary intake 342 
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There was a main effect of week on total calorie (P=0.02) and carbohydrate (P=0.02) intake, 343 
although no main effect of supplement or a supplement x week interaction (all P>0.05). There 344 
were no main effects of supplement, week, or supplement x week interactions for total protein or 345 
fat intake (all P>0.05). The intake of β-alanine did not differ between groups (P=0.525), and was 346 
unchanged over the supplementation period (P=0.203); similarly, there was no supplement x 347 
week interaction (P=0.224; Table, Supplemental Digital Content 4, Food intake in BA and PL 348 
during weeks 4-8 and 16-20 of supplementation).  349 
350 
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DISCUSSION 351 
This is the first study to systematically examine the effects of longer-term β-alanine 352 
supplementation on muscle carnosine content, carnosine-related genes and high-intensity 353 
exercise capacity at monthly intervals. The novel findings (Figure 4) are that twenty-four weeks 354 
of β-alanine supplementation increased muscle carnosine content from baseline at every time 355 
point, although the absolute and the time to the highest recorded content was variable between 356 
individuals. TauT was down-regulated with chronic β-alanine supplementation. High-intensity 357 
cycling capacity was improved, with improvements associated with changes in muscle carnosine.  358 
 359 
Muscle carnosine content increased by 55% following 4 weeks, which is lower than the relative 360 
increases previously shown using HPLC analysis of muscle biopsy samples (17, 19), despite the 361 
lower dose of β-alanine used in those studies (mean 5.2 g·day-1; (17, 19)). Absolute changes in 362 
muscle carnosine at 4 weeks in the present study were greater than those shown by Harris et al. 363 
(17) but identical to those of Hill et al. (19), despite that in the previous studies a slightly lower 364 
dose (5.2 versus 6.4g·day
-1
) was given. The greatest absolute change in mean carnosine content 365 
occurred following 20 weeks of supplementation, and corresponded to a +98±40% increase. This 366 
is lower than the +143±151% increases shown by Chung et al. (10) using 
1
H-MRS following 4 367 
weeks of β-alanine supplementation, although the absolute changes appear quite similar when 368 
both data sets are expressed in the same units. Percentage increases misrepresent carnosine 369 
changes in muscle, particularly in those with low initial values (i.e., predominant distribution of 370 
type I fibres; low meat eaters or vegetarians). Since the contribution of carnosine to muscle 371 
buffering capacity (or indeed any suggested physiological mechanism) is dependent upon its 372 
actual content in muscle, any exercise or therapeutic benefits received via this mechanism will 373 
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depend on the absolute changes in muscle content. The discrepancy between changes in muscle 374 
carnosine content and concentration (i.e., absolute vs. percentage change) highlights the 375 
necessity in determining absolute changes in muscle carnosine content, particularly in studies in 376 
which carnosine accumulation is associated with other physiological outcomes (e.g., gene 377 
expression or exercise responses).  378 
 379 
We hypothesised that changes in muscle carnosine content would be mirrored by changes in the 380 
expression of carnosine-related genes. TauT was downregulated with supplementation, although 381 
no other changes in gene expression were shown. Since TauT is the primary transporter of β-382 
alanine into muscle (4), our data support the suggestion that increases in muscle carnosine may 383 
be more dependent upon the transport of β-alanine into the muscle than the activity of carnosine 384 
synthase (CARNS; (14)), since this will directly influence the availability of β-alanine for muscle 385 
carnosine synthesis. Decreasing the activity of TauT during prolonged increases in circulating β-386 
alanine through oral supplementation may be the body’s mechanism to best maintain 387 
intramuscular homeostasis of muscle carnosine by limiting the uptake of β-alanine into muscle. 388 
Blancquaert et al. (8) suggested that the homeostasis of muscle carnosine is tightly regulated by 389 
the transamination of circulating levels of β-alanine via GABA-T and AGXT2; the current data 390 
suggest that the downregulation of TauT can also play a role in the regulation of muscle 391 
carnosine content, perhaps contributing to increased transamination of circulating levels due to 392 
decreased uptake into muscle, although this was not measured here. The lack of any other 393 
changes in gene expression in this study is in contrast to the increased expression of CARNS, 394 
TauT and ABAT shown following β-alanine supplementation in mice (14). However, the dose of 395 
β-alanine that these mice received is equivalent to a supra-physiological dose in humans and it is 396 
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unclear when the mice received their final dose in relation to the timing of analysis. In the 397 
current study, participants were requested to arrive at the laboratory four hours following the 398 
ingestion of a dose of β-alanine. These results are understandable given circulating levels of β-399 
alanine return to normal 4 hours following an equivalent dose (17). A limitation of our study is 400 
that only gene expression was analysed; post-transcriptional events may result in disparate 401 
kinetics  between gene and protein expression, influencing inferences (25). Further research 402 
should ascertain whether expression of these genes and proteins is modified in the hours 403 
following acute β-alanine ingestion and whether these change over time with prolonged 404 
supplementation.  405 
 406 
The highest carnosine contents ranged from 31.79 to 63.92 mmol·kg
-1
dm, and were dependent 407 
on the initial content in muscle. Interestingly, five individuals showed their highest values at 24 408 
weeks, with four of those still showing increases in excess of 6 mmol·kg
-1
dm from the previous 409 
time point. For these participants it is possible that further increases in carnosine would have 410 
occurred with additional supplementation. The variability in the kinetics of carnosine 411 
accumulation shown here is unlike that of creatine in muscle, since 5-7 days of creatine 412 
supplementation at a dose of 20 to 30 g·day
-1
 is sufficient to reach maximal content which falls 413 
within a narrow physiological range across individuals (140-160 mmol·kg
-1
dm; (16, 29)). Lower 414 
initial doses of creatine supplementation lead to a longer time-to-peak content in individuals 415 
(23). Although one individual attained maximal content within four weeks of supplementation, 416 
the remaining participants showed maximal content during the final twelve weeks of 417 
supplementation. It cannot be dismissed that the current supplementation protocol may have 418 
been suboptimal in attaining peak carnosine content in muscle. The effects of higher or lower 419 
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doses may result in a different expression profiles in the genes or enzymes associated with 420 
carnosine synthesis (i.e., lower downregulation of TauT) and further investigation is warranted to 421 
determine whether maximal content can be attained sooner.  422 
 423 
Trained individuals have greater increases in muscle carnosine concentration with 424 
supplementation (7), possibly as a result of better delivery of β-alanine to the muscle due to 425 
increased blood flow (28), while it could also be due to a contraction-induced stimulation of 426 
TauT (7). Thus, increased expression of the β-alanine transporter (or an attenuation of its down 427 
regulation) may lead to an increased carnosine accumulation with supplementation. It remains to 428 
be determined whether muscle contraction per se increases the activity of β-alanine transporters, 429 
and greater increases with supplementation in highly trained individuals cannot be ruled out. 430 
 431 
All individuals increased muscle carnosine from initial content with supplementation, which 432 
suggests that all individuals can show some degree of carnosine accumulation following β-433 
alanine supplementation. Mean muscle carnosine contents increased most in the first 4 weeks, 434 
although this quickly dropped off as evidenced by a difference from the previous time point only 435 
at week 4. Nonetheless, an increased content in the final weeks of supplementation from the first 436 
eight suggest that total content continued to increase. Stellingwerff et al. (33) showed a linear 437 
response with supplementation with a high dependence on initial concentrations and the total 438 
amount of β-alanine consumed, which explained ~80% of the variance in carnosine 439 
concentration in their study. Although the initial carnosine content in the present study was 440 
related to the content at several time points and the maximal content attained, individual analysis 441 
revealed that not all individuals increased carnosine content linearly. These differences may be 442 
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related to the two lower doses used in the aforementioned study (1.6 and 3.2 g·d
-1
), which 443 
resulted in far lower increases in muscle carnosine concentration. Thus, it appears that the uptake 444 
kinetics of muscle carnosine content may be dependent upon the dose ingested. 445 
 446 
These are the first data to show that muscle carnosine may not increase continuously until 447 
maximal content in all individuals, given that carnosine content decreased at certain time points 448 
across the 24-week period. Interestingly, these decreases occurred despite on-going 449 
supplementation with β-alanine. The physiological mechanisms underpinning this response can 450 
only be speculated upon but may include a down regulation of the transport of β-alanine into the 451 
muscle cell, a reduction in the activity of the carnosine synthase enzyme or an increased 452 
degradation of carnosine by carnosinases. These possibilities seem unlikely to explain the results 453 
of the current study, given that we only showed an effect of β-alanine on TauT, although we 454 
determined the relative expression of the genes that encode their associated protein(s), which can 455 
be dependent on sampling time. Other possible explanations include the potential for 456 
experimental or analytical error, although we feel this is unlikely given the control measures that 457 
were undertaken to ensure the quality of muscle sampling, the extraction procedure and the 458 
HPLC analysis. One other clear possibility is that the location of the muscle biopsy contributed 459 
to the changes in muscle carnosine content across the study due to sample to sample differences 460 
in the amount of type I and II muscle fibres collected in the biopsy sample. Since muscle 461 
carnosine is not homogeneously distributed across muscle fibres in the m. vastus lateralis (19), 462 
this may have resulted in variation between biopsies. It is, however, unlikely that these 463 
differences within the same mixed muscle sample would have accounted for the magnitude of 464 
the changes observed in muscle carnosine content. In addition, muscle carnosine content varied 465 
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by ~17% within the placebo group across twenty-four weeks, which is similar to those shown in 466 
the m. gastrocnemius over 9 weeks.(3) These interesting and novel findings pose several 467 
important questions worthy of further investigation, including a) why some individuals show 468 
decrements in muscle carnosine with β-alanine supplementation and others do not, b) what 469 
physiological mechanisms contribute to this process, and c) what is the biochemical fate of the 470 
carnosine that is eliminated from the skeletal muscle.  471 
 472 
Supplementation with β-alanine improved exercise capacity and MBIs showed possible to almost 473 
certain improvements across all weeks with β-alanine with effect sizes suggesting moderate to 474 
very large effects. Similar exercise improvements have been shown using the CCT110% on three 475 
independent occasions following 4 weeks of β-alanine supplementation (12-14%; (11, 19, 30)), 476 
with further improvements following 10 weeks of supplementation (~16%; (19)). Thus, it was 477 
hypothesised that greater exercise improvements would be shown in the current study when 478 
supplementation was extended past 10 weeks, although this was not the case. The smaller 479 
improvements shown here may have been due to large variability in exercise responses, perhaps 480 
due to differences in the buffering contribution of carnosine between individuals. The buffering 481 
contribution of carnosine has been estimated to be ~8%, although it is likely to be higher (19). 482 
Since its relative contribution to muscle buffering is dependent on total buffering capacity, it 483 
could be postulated that some individuals may be less responsive to changes in muscle carnosine 484 
content than others. However, this could not explain why no individual’s peak performance 485 
coincided with their peak muscle carnosine content; it cannot currently be ruled out that changes 486 
in muscle buffering are offset by changes in other compounds. Nonetheless, exercise capacity in 487 
the current study was associated with muscle carnosine content and data suggests that 24 weeks 488 
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of β-alanine supplementation improves high-intensity exercise capacity, although variability 489 
exists with several less or non-responsive individuals. Future studies should evaluate exercise 490 
capacity with β-alanine supplementation on multiple occasions to account for variability in 491 
exercise responses. 492 
 493 
In conclusion, twenty-four weeks of β-alanine supplementation increased muscle carnosine 494 
content up to ~64 mmol
.
kg
-1
dm, although maximal absolute changes were variable (i.e., +17 to 495 
+41 mmol
.
kg
-1
dm), as was the time-to-maximal content. The transporter TauT was 496 
downregulated with β-alanine supplementation, suggesting it plays an important role in the 497 
accumulation of muscle carnosine content during prolonged β-alanine supplementation. Exercise 498 
capacity was improved with supplementation, mirroring changes in muscle carnosine, although a 499 
certain amount of variation was shown. Collectively, these results highlight the variability in 500 
changes in muscle carnosine content between individuals and that a maximal accumulation of 501 
muscle carnosine may not occur within twenty-four weeks at a high dose for all individuals, 502 
suggesting that determinants other than the availability of β-alanine may have a major influence 503 
on muscle carnosine content. 504 
505 
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FIGURES 630 
Figure 1. Panel A: Experimental design of the study. Panel B: Main trial design. Wmax = 631 
maximum cycling power output test; CCT110% = Cycling capacity test at 110% of maximum 632 
cycling power output.  633 
 634 
Figure 2. Panel A: Muscle carnosine content throughout supplementation in BA (black circles) 635 
and PL (white circles). Panel B: Absolute change in muscle carnosine content from Week 0 in 636 
BA (black bars) and PL (white bars). Panel C: Time-to-exhaustion throughout supplementation 637 
in BA (black circles) and PL (white circles). Panel D: Absolute change in time-to-exhaustion 638 
from Week 0 in BA (black bars) and PL (white bars). 
a
P≤0.0001 from Week 0. bP≤0.0001 from 639 
PL at same time point. 
c
P≤ 0.05 from Weeks 4 and 8. Data are mean±1SD.  640 
 641 
Figure 3. Fold change across the 24 weeks for CARNS, TauT, ABAT, CNDP2, PAT1, PHT1 and 642 
PEPT2. 
*
P=0.002 Main effect of BA. 643 
 644 
Figure 4. Overview of the analyses and results of the current study. There was a downregulation 645 
in the TauT transporter which transports β-alanine into muscle; the other β-alanine transporter, 646 
PAT1, was unaffected. Similarly, no changes were shown in the histidine/carnosine transporters 647 
PHT1 and PEPT2, which intramuscular expression of CARNS and CNDP2, which code 648 
carnosine synthase (Carn. Synth.) and carnosinase (CN2) was also unchanged. There was no 649 
change in the expression of ABAT, which encodes the protein responsible for intracellular 650 
transamination of β-alanine. There was an increase in muscle carnosine content over the 24 week 651 
period, which resulted in an improved high-intensity cycling capacity.  652 
653 
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Supplemental Digital Content 1.doc Forward and reverse primer sets for all genes analysed 655 
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Supplemental Digital Content 2.tiff Panel A: Muscle carnosine content and time-to-exhaustion 658 
across the supplementation period in BA (r=0.82, r
2
=0.68, P=0.02). Panel B: Absolute change 659 
(∆) in muscle carnosine content and absolute change (∆) in time-to-exhaustion across the 660 
supplementation period in BA (r=0.804, r
2
=0.65, P=0.05).  661 
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1SD) at pre-exercise, post-exercise and 5-min post-exercise at every week in BA and PL. 664 
*P<0.001 from Pre-exercise. 665 
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Supplemental Digital Content 4.doc Food intake (mean ± 1SD) in BA and PL during weeks 4-8 667 
and 16-20 of supplementation. *P=0.02 Main effect of Week. 668 
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Table 1.
1
 682 
Participant 
number 
Week 0 
(mmol
.
kg
-1
dm) 
Maximal content 
(mmol
.
kg
-1
dm) 
Absolute maximal 
change 
(mmol
.
kg
-1
dm) 
Percentage 
maximal change 
(%) 
Time-to-
maximum 
(weeks) 
1 11.67 31.79 20.13 172.5 20 
2 26.97 45.42 18.45 68.4 16 
3 19.84 41.94 22.10 111.4 4 
4 22.60 63.92 41.32 182.8 12 
5 19.19 39.89 20.71 107.9 24 
8 19.86 39.29 19.44 97.9 20 
10 28.49 59.80 31.31 109.9 24 
13 22.99 45.18 22.19 96.5 24 
14 22.26 47.42 25.16 113.1 24 
16 18.34 54.94 36.60 199.6 24 
17 21.71 41.57 19.86 91.5 12 
18 28.97 46.10 17.13 59.1 12 
22 26.96 54.76 27.80 103.1 20 
23 22.50 59.81 37.31 165.8 20 
25 23.29 48.62 25.34 108.8 12 
Mean 22.37 48.03 25.66 119.2 18 
SD 4.46 8.97 7.63 41.5 6 
Min 11.67 31.79 17.13 59.1 4 
Max 28.97 63.92 41.32 199.6 24 
 683 
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1
 Table 1. Individual maximal muscle carnosine changes to supplementation in BA. 
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Table 2.
2
 685 
 686 
(vs. Week 0) TTE 
 BA  PL 
 %change MBI ES  %change MBI ES 
Week 4 +5.7±8.7 89%; likely 0.62  +1.8±14.4 31%; possible 0.08 
Week 8 +2.4±12.6 41%; possible 0.25  +1.2±11.9 21%; unlikely 0.01 
Week 12 +4.8±13.8 70%; possible 0.31  -1.3±18.3 15%; unlikely -0.21 
Week 16 +8.8±12.0 96%; very likely 0.80  +0.1±15.6 19%; unlikely -0.09 
Week 20 +12.3±10.4 
100%; almost 
certainly 
1.21  -7.1±9.9 
1%; almost 
certainly not 
-0.47 
Week 24 +9.7±13.5 96%; very likely 0.83  +0.3±17.5 25%; unlikely -0.01 
 687 
                                                 
2
 Table 2. Likelihood of a positive improvement in TTE (%; qualitative) as determined by MBI and ES at every 
week versus Week 0. 
